See more : Yue Yuen Industrial (Holdings) Limited (0551.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Precipio, Inc. (PRPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precipio, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Tribeca Global Natural Resources Limited (TGF.AX) Income Statement Analysis – Financial Results
- Sanquan Food Co., Ltd. (002216.SZ) Income Statement Analysis – Financial Results
- Oakridge International Limited (U9O0.F) Income Statement Analysis – Financial Results
- Gibson Energy Inc. (GEI.TO) Income Statement Analysis – Financial Results
- Adani Green Energy Limited (ADANIGREEN.BO) Income Statement Analysis – Financial Results
Precipio, Inc. (PRPO)
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.20M | 9.41M | 8.85M | 6.09M | 3.13M | 2.86M | 1.72M | 1.56M | 1.65M | 27.08M | 27.54M | 31.48M | 31.97M | 20.05M | 22.02M | 23.99M | 23.18M | 23.42M | 25.83M | 33.79M | 33.87M | 37.55M | 38.47M | 25.88M | 23.03M |
| Cost of Revenue | 9.18M | 6.90M | 6.46M | 4.94M | 2.91M | 2.64M | 1.43M | 1.76M | 1.94M | 17.36M | 15.05M | 16.47M | 13.53M | 10.28M | 10.42M | 10.35M | 10.48M | 12.05M | 13.50M | 24.60M | 24.32M | 19.57M | 17.20M | 10.89M | 10.58M |
| Gross Profit | 6.02M | 2.51M | 2.39M | 1.15M | 219.00K | 225.00K | 292.00K | -205.00K | -287.00K | 9.72M | 12.50M | 15.01M | 18.44M | 9.76M | 11.61M | 13.65M | 12.69M | 11.37M | 12.33M | 9.19M | 9.55M | 17.99M | 21.27M | 14.99M | 12.46M |
| Gross Profit Ratio | 39.60% | 26.67% | 27.03% | 18.88% | 7.00% | 7.86% | 16.95% | -13.17% | -17.36% | 35.89% | 45.37% | 47.68% | 57.67% | 48.70% | 52.69% | 56.88% | 54.77% | 48.55% | 47.74% | 27.21% | 28.20% | 47.89% | 55.29% | 57.92% | 54.09% |
| Research & Development | 0.00 | 1.70M | 1.30M | 1.20M | 1.20M | 1.10M | 500.00K | 1.42M | 1.85M | 2.90M | 3.21M | 2.49M | 2.22M | 2.31M | 3.18M | 2.47M | 3.03M | 2.36M | 2.20M | 6.69M | 9.31M | 12.20M | 9.37M | 7.65M | 6.30M |
| General & Administrative | 10.32M | 13.51M | 10.61M | 9.00M | 8.32M | 9.45M | 6.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 8.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.42M | 13.61M | 10.71M | 9.10M | 8.42M | 9.45M | 6.49M | 6.19M | 7.06M | 24.15M | 25.04M | 22.02M | 19.15M | 10.93M | 10.32M | 10.80M | 11.47M | 12.14M | 12.22M | 17.50M | 17.32M | 24.20M | 21.64M | 14.91M | 11.53M |
| Other Expenses | 3.22M | 15.31M | 12.01M | 10.30M | 9.62M | -1.33M | 877.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 425.00K | 10.50M | 4.77M | 0.00 | 0.00 | 1.91M | 1.51M |
| Operating Expenses | 13.64M | 15.31M | 12.01M | 10.30M | 9.62M | 9.45M | 6.49M | 7.61M | 8.91M | 27.04M | 28.26M | 24.51M | 21.37M | 13.24M | 13.50M | 13.26M | 14.50M | 14.50M | 14.84M | 34.68M | 31.40M | 36.40M | 31.01M | 24.47M | 19.34M |
| Cost & Expenses | 22.82M | 22.21M | 18.46M | 15.24M | 12.53M | 12.09M | 7.92M | 9.38M | 10.85M | 44.41M | 43.30M | 40.98M | 34.90M | 23.52M | 23.92M | 23.61M | 24.98M | 26.55M | 28.34M | 59.28M | 55.72M | 55.97M | 48.21M | 35.36M | 29.92M |
| Interest Income | 0.00 | 12.00K | 20.00K | 470.00K | 2.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 74.00K | 270.00K | 216.00K | 0.00 | 0.00 | 160.00K | 626.00K | 2.45M | 2.01M | 0.00 |
| Interest Expense | 18.00K | 12.00K | 20.00K | 470.00K | 473.00K | 0.00 | 2.32M | 0.00 | 0.00 | 665.00K | 642.00K | 888.00K | 958.00K | 4.00K | 15.00K | 74.00K | 0.00 | 11.00K | 1.98M | 2.38M | 315.00K | 62.00K | 58.00K | 1.78M | 0.00 |
| Depreciation & Amortization | 1.52M | 1.52M | 1.44M | 1.36M | 1.35M | 1.27M | 743.00K | 112.00K | 489.00K | 2.25M | 2.75M | 2.28M | 2.10M | 708.00K | 855.00K | 882.00K | 950.00K | 1.95M | 4.28M | 4.01M | 8.75M | 3.99M | 3.68M | 1.91M | 1.51M |
| EBITDA | -4.32M | -10.65M | -7.05M | -8.77M | -8.22M | -7.96M | -5.45M | -1.60M | -8.65M | -10.51M | -12.65M | -5.02M | -830.00K | -2.27M | -1.04M | 600.00K | -981.00K | -973.00K | 1.77M | -6.76M | -7.44M | -18.28M | -6.06M | -7.57M | -5.37M |
| EBITDA Ratio | -28.41% | -119.82% | -92.32% | -109.24% | -205.50% | -111.66% | 353.86% | -523.12% | -513.43% | -80.83% | -58.52% | -22.95% | 15.70% | -16.26% | -8.62% | 8.39% | -1.99% | -5.02% | 10.32% | -12.99% | -21.96% | -29.33% | -15.67% | -32.22% | -23.31% |
| Operating Income | -7.62M | -12.80M | -9.61M | -9.15M | -9.40M | -13.91M | -15.51M | -7.82M | -9.20M | -17.32M | -15.76M | -9.50M | -2.97M | -3.61M | -1.90M | -368.00K | -3.32M | -3.13M | -2.51M | -29.06M | -22.59M | -21.70M | -9.74M | -9.48M | -6.88M |
| Operating Income Ratio | -50.14% | -135.96% | -108.63% | -150.13% | -300.74% | -485.75% | -900.23% | -502.18% | -556.26% | -63.96% | -57.21% | -30.19% | -9.30% | -18.02% | -8.61% | -1.53% | -14.33% | -13.37% | -9.72% | -86.00% | -66.70% | -57.78% | -25.32% | -36.61% | -29.88% |
| Total Other Income/Expenses | 1.77M | 619.00K | 1.10M | -1.45M | -2.32M | -2.06M | -5.18M | -515.00K | -1.22M | 3.90M | -282.00K | 1.32M | -6.77M | 628.00K | 18.00K | 86.00K | 243.00K | 198.00K | -2.45M | -5.26M | -5.82M | -2.98M | 2.36M | 996.00K | -1.20M |
| Income Before Tax | -5.85M | -12.18M | -8.52M | -10.60M | -13.31M | -15.97M | -20.69M | -8.27M | -10.14M | -13.42M | -16.04M | -8.18M | -9.74M | -2.98M | -1.88M | -282.00K | -1.93M | -2.93M | -4.96M | -34.47M | -22.89M | -21.26M | -7.38M | -8.48M | -8.08M |
| Income Before Tax Ratio | -38.51% | -129.39% | -96.25% | -173.97% | -425.74% | -557.72% | -1,201.04% | -531.09% | -613.31% | -49.54% | -58.24% | -25.99% | -30.46% | -14.88% | -8.53% | -1.18% | -8.33% | -12.53% | -19.20% | -102.00% | -67.60% | -56.61% | -19.18% | -32.77% | -35.08% |
| Income Tax Expense | 0.00 | 25.00K | 33.00K | 1.63M | -70.00K | -279.00K | 13.87M | -203.00K | 23.76M | 524.00K | -54.00K | 146.00K | 45.00K | 150.00K | 42.00K | 213.00K | 243.00K | 30.00K | 26.00K | -94.00K | 65.00K | 105.00K | 24.00K | 180.00K | 1.75M |
| Net Income | -5.85M | -12.20M | -8.55M | -12.23M | -13.24M | -15.69M | -20.69M | -7.62M | -32.95M | -13.94M | -15.99M | -8.33M | -9.78M | -3.13M | -1.92M | -495.00K | -2.11M | -3.43M | -14.99M | -34.37M | -22.96M | -21.37M | -7.40M | -8.66M | -9.83M |
| Net Income Ratio | -38.51% | -129.65% | -96.62% | -200.76% | -423.50% | -547.97% | -1,201.04% | -489.15% | -1,993.59% | -51.48% | -58.04% | -26.45% | -30.60% | -15.63% | -8.72% | -2.06% | -9.09% | -14.65% | -58.05% | -101.73% | -67.79% | -56.89% | -19.24% | -33.46% | -42.66% |
| EPS | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.81 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| EPS Diluted | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.80 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| Weighted Avg Shares Out | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
| Weighted Avg Shares Out (Dil) | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
Precipio Announces Q3-2023 Shareholder Update Call
NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET.
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from...
Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Company anticipates current cash levels sufficient to reach breakeven Company anticipates current cash levels sufficient to reach breakeven
Precipio Continues to Sign New HemeScreen™ Customers
NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M.
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) today announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the company's common stock in order...
Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces its Pathology Division has in August exceeded the monthly breakeven revenue goal which, if continued, causes this division to contribute cash...
Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q2 2023 Earnings Conference Call August 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Second Quarter 2023 Shareholder Update Conference Call. All participants will be...
Precipio Announces Q2-2023 Shareholder Update Call
NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET.
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on...
Source: https://incomestatements.info
Category: Stock Reports